SRTA

Business Context and Reporting Period

Company: Blade Air Mobility, Inc. (BLDE)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2025
Business Overview: Blade operates an asset-light air mobility platform providing passenger transport (helicopter, fixed-wing, and jet charters) and medical logistics (organ transport). The company is transitioning toward Electric Vertical Aircraft (EVA) technology. Operations are concentrated in the Northeast U.S. and Southern Europe.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 5.4% to $54.3 million. This was driven by a 59.9% surge in "Jet and Other" revenue ($9.1M vs $5.7M) and growth in European short-distance operations, partially offset by a 5.4% decline in U.S. Short Distance revenue following the discontinuation of Canadian operations in August 2024.
• Profitability Improvement: Net loss narrowed by 17.5% to $3.5 million. Adjusted EBITDA improved significantly by 65.1% to a loss of $1.2 million, primarily due to operational leverage in the Passenger segment and reduced marketing spend.
• Margin Expansion: Gross margin expanded to 14.9% from 11.4%, and Flight margin increased to 22.1% from 19.7%. Cost of revenue as a percentage of revenue decreased from 80% to 78%.
• Cash Flow: Operating cash burn improved dramatically, with net cash used in operating activities dropping from $15.6 million in Q1 2024 to only $0.2 million in Q1 2025. This was aided by working capital management (decreased prepaids, increased deferred revenue) and non-cash adjustments.
• Investment Activity: The company maintained a net positive cash flow from investing activities ($20.4M) due to the maturity of held-to-maturity securities exceeding new purchases.

Guidance, Outlook, and Risks

• Outlook: Management anticipates sufficient liquidity ($120 million) to meet operational needs for at least the next 12 months. No additional capital is currently expected to be needed for the current business plan.
• Strategic Focus: Continued transition to EVA technology, expansion of "by-the-seat" passenger products, and optimization of the owned aircraft fleet in the Medical segment.
• Stock Repurchase Program: A $20.0 million repurchase program remains active with approximately $19.8 million capacity remaining; no shares were repurchased in Q1 2025.
• Risks & Contingencies:
  • Legal: Ongoing litigation regarding the 2021 merger (Drulias et al. v. Affeldt, et al.) involving claims of breach of fiduciary duty. Management intends to defend vigorously.
  • Operational: Reliance on third-party operators for aircraft; potential for increased fuel costs and insurance premiums; seasonality in the Passenger segment (Q1/Q4 typically lower volume).
  • Regulatory: Uncertainty regarding FAA certification timelines for EVA aircraft.

Investor Verification Checklist

• Liquidity Runway: Verify the sustainability of the $120 million liquidity position given the continued net losses and capital expenditure requirements for fleet maintenance and expansion.
• Medical Segment Utilization: Confirm the impact of lower utilization of the newly acquired owned aircraft fleet on future Medical segment margins.
• Warrant Liability Volatility: Monitor the fair value of warrant liabilities ($3.1M), as fluctuations significantly impact reported net income but are non-cash.
• Legal Exposure: Assess potential financial impact of the Drulias class action lawsuit, though management currently deems the risk immaterial.
• Seasonality Trends: Validate if Q1 results are indicative of full-year performance or if significant Q2/Q3 seasonality will drive the majority of annual revenue.